Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $34.00 price objective on the stock. Wedbush’s price objective would indicate a potential upside of 72.68% from the stock’s previous close.

Several other equities analysts also recently commented on KNSA. Evercore ISI raised their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $19.69 on Tuesday. The company has a market capitalization of $1.42 billion, a PE ratio of -140.63 and a beta of 0.32. Kiniksa Pharmaceuticals has a one year low of $16.56 and a one year high of $28.15. The business has a 50 day simple moving average of $19.68 and a 200 day simple moving average of $22.57.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.35 EPS. Equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,092 shares of company stock worth $745,589. 54.57% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Braidwell LP grew its stake in shares of Kiniksa Pharmaceuticals by 19.3% during the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock worth $68,289,000 after purchasing an additional 557,934 shares during the period. Nuveen Asset Management LLC grew its stake in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals by 50.9% during the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock worth $15,422,000 after purchasing an additional 263,146 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock worth $15,262,000 after purchasing an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in shares of Kiniksa Pharmaceuticals by 1.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company’s stock worth $15,141,000 after purchasing an additional 10,209 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.